Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of il-20 antagonist in the treatment of rheumatoid arthritis and osteoporosis

A technology for osteoporosis and antagonists, applied in the field of application of IL-20 antagonists in the treatment of rheumatoid arthritis and osteoporosis, can solve the problems of few and few

Inactive Publication Date: 2011-12-14
LBL BIOTECH INC
View PDF70 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, little is known about the role of IL-20 in bone resorption, or the function of IL-20 in RANKL-RANK signaling-mediated osteoclastogenesis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of il-20 antagonist in the treatment of rheumatoid arthritis and osteoporosis
  • Application of il-20 antagonist in the treatment of rheumatoid arthritis and osteoporosis
  • Application of il-20 antagonist in the treatment of rheumatoid arthritis and osteoporosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0180] Embodiment 1, treating rheumatoid arthritis with monoclonal antibody 7E (mAb 7E)

[0181] Mice with collagen-induced arthritis (CIA) are suitable animal models for the study of human rheumatoid arthritis, and this study will test monoclonal antibody 7E (mAb 7E) treatment in this model effects of such diseases.

[0182] In this study, eight-week-old male Sprague-Dawley rats will be induced to suffer from CIA disease by the method described below. First, 200 μl of emulsion was injected into the skin (back) of rats to generate an initial immune response, wherein the emulsion contained Freund's complete adjuvant, 4 mg / ml of heat-killed Mycobacterium tuberculosis (Mycobacterium Tuberculosis (Arthrogen-CIA Chondrex, Redmond, WA, USA)) and bovine collagen type II (CH; 2 mg / ml dissolved in 0.05 M acetic acid) were used to form an injection emulsion with a volume ratio of 1:1:1. Eight days later, 100 μl of the same emulsion was injected into the base of the rat's tail throug...

Embodiment 2

[0189] Example 2, Simultaneous use of mAb 7E and Etanercept in the treatment of rheumatoid arthritis

[0190] The method as in Example 1 was used to induce the onset of CIA in rats, and the rats suffering from CIA were randomly divided into five groups (n=9 in each group). After the onset of CIA, they were treated three times a week according to the following reagents : Group 1: PBS; Group 2: Mouse IgG (obtained from Chemicon International, Inc., Temecula, CA, USA); Group 3: Etanercept (6 mg / kg, s.c.); Group 4: mAb 7E (6 mg / kg, s.c.); Group 5: mAb 7E (3 mg / kg, s.c.) and Etanercept (3 mg / kg, s.c.). First, the thickness of the hind paw of each rat treated with the reagent was measured by the method described in Example 1. Experimental results showed that compared with treatment with mAb 7E or Etanercept alone, treatment of rats with mAb 7E and Etanercept at the same time could significantly reduce the thickness of hind paws of rats with CIA.

[0191] Then, the method propos...

Embodiment 3

[0201] Embodiment 3, treat osteoporosis with mAb7E

[0202] Fourteen-week-old female BALB / C mice (provided by the Experimental Animal Center of National Cheng Kung University, Tainan) were used to adapt them to an environment-controlled laboratory for 4 days, and the mice were assigned to a temperature / humidity control room (20 -25°C and 40-45%) in polycarbonate cages (3 per cage). The light:dark cycle was set at 12-hour light:12-hour dark, and self-obtained food and water were provided. Afterwards, the mice were generally anesthetized, given pentobarbital (given at a rate of 50 mg / kg of mouse body weight; Sigma-Aldrich, St.Louis, MO), and then the animals were subjected to dorsal ovariectomy (dorsal ovariectomized, OVX) or sham controls (Sham controls). Among them, the sham control group refers to that the mice undergo surgery to expose the ovaries on both sides, and then the skin of the mice is sutured without being removed. After the mice subjected to OVX surgery or co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention features methods and compositions for preventing or treating rheumatoid arthritis and osteoporosis by administering an antagonist of IL-20. The IL-20 antagonist may be an anti-IL-20 antibody, such as mAB 7E, that is capable of binding human IL-20 and blocking IL-20 interaction with its receptors.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of US Patent Application Serial No. 12 / 246,715, filed October 7, 2008, and US Provisional Patent Application Serial No. 61 / 238,661, filed August 31, 2009. Each application is hereby incorporated by reference in its entirety. field of invention [0003] The present invention relates to the application of IL-20 antagonist in preventing, delaying the onset of osteoporosis and rheumatoid arthritis (rheumatoid arthritis, rheumatoid arthritis) or treating osteoporosis and rheumatoid arthritis. Background of the invention [0004] Osteoporosis is characterized by low bone mass and loss of bone tissue, resulting in weakened and fragile bones. Net bone loss can be caused by various factors, such as low estrogen, abnormal intake of calcium and vitamin D, and inflammation. In the case of postmenopausal osteoporosis, the main etiology is bone resorption. Osteoporosis is a disease of impaired ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395
CPCA61K2039/505A61K39/3955C07K2319/30C07K2316/96C07K2319/32C07K2317/76C07K16/244A61P15/12A61P19/00A61P19/02A61P19/10A61P29/00A61P43/00A61P5/26A61P5/30A61K2300/00A61K39/395
Inventor 张明熙
Owner LBL BIOTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com